Medincell’s partner Teva provides new update on pivotal Phase 3 clinical trial of investigational drug Olanzapine Long-Acting Injectable (LAI) Page 1

Regulatory News:

Medincell (Paris:MEDCL):

Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced at the 22nd^nd Annual Global Healthcare Conference held yesterday indicated that c.99% of targeted injections for submission have been performed to date (replay available here). Teva also confirmed that full safety results for submission are expected to be available in H2 24.

Olanzapine LAI is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic Olanzapine. It has the potential to be the first long-acting Olanzapine with a favorable safety profile, as other Olanzapine LAIs have been associated with an FDA black box warning for PDSS limiting their use.